[go: up one dir, main page]

MXPA04005033A - Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. - Google Patents

Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.

Info

Publication number
MXPA04005033A
MXPA04005033A MXPA04005033A MXPA04005033A MXPA04005033A MX PA04005033 A MXPA04005033 A MX PA04005033A MX PA04005033 A MXPA04005033 A MX PA04005033A MX PA04005033 A MXPA04005033 A MX PA04005033A MX PA04005033 A MXPA04005033 A MX PA04005033A
Authority
MX
Mexico
Prior art keywords
metformin
combination
pharmaceutical composition
oxobutanoic acid
treating diabetes
Prior art date
Application number
MXPA04005033A
Other languages
English (en)
Inventor
Marais Dominique
Original Assignee
Merck Patent Ges Mit Baschrank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Baschrank filed Critical Merck Patent Ges Mit Baschrank
Publication of MXPA04005033A publication Critical patent/MXPA04005033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con una composicion farmaceutica que comprende como principios activos, metformina, opcionalmente en forma de una de sus sales farmaceuticamente aceptables y un acido 4-oxobutanoico, en combinacion con uno o mas excipientes farmaceuticamente aceptables. Estas composiciones son particularmente adecuadas para el tratamiento contra diabetes no dependientes de insulina.
MXPA04005033A 2001-11-28 2002-11-06 Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. MXPA04005033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0115398A FR2832633B1 (fr) 2001-11-28 2001-11-28 Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
PCT/EP2002/012355 WO2003045368A1 (en) 2001-11-28 2002-11-06 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes

Publications (1)

Publication Number Publication Date
MXPA04005033A true MXPA04005033A (es) 2004-08-11

Family

ID=8869889

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005033A MXPA04005033A (es) 2001-11-28 2002-11-06 Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.

Country Status (22)

Country Link
US (1) US20050020609A1 (es)
EP (1) EP1448181B1 (es)
JP (1) JP2005515984A (es)
KR (1) KR20040058266A (es)
CN (1) CN1592615A (es)
AT (1) ATE327746T1 (es)
AU (1) AU2002351848A1 (es)
BR (1) BR0214487A (es)
CA (1) CA2468280A1 (es)
CY (1) CY1105165T1 (es)
DE (1) DE60211938T2 (es)
DK (1) DK1448181T3 (es)
ES (1) ES2266605T3 (es)
FR (1) FR2832633B1 (es)
HU (1) HUP0402241A2 (es)
MX (1) MXPA04005033A (es)
PL (1) PL369894A1 (es)
PT (1) PT1448181E (es)
RU (1) RU2004119817A (es)
TW (1) TW200300341A (es)
WO (1) WO2003045368A1 (es)
ZA (1) ZA200405021B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1752147A4 (en) * 2004-06-04 2007-10-31 Kowa Co MEDICAMENT FOR THE PREVENTION OR TREATMENT OF DIABETES
EP1792580A1 (en) 2005-09-27 2007-06-06 Ziterion GmbH Two-part dental implants made of biocompatible ceramics
EP1967157A1 (en) 2007-03-05 2008-09-10 Ziterion GmbH Hybrid two-part dental implant
EP2106767A1 (en) 2008-03-31 2009-10-07 Ziterion GmbH Two-part dental implant
GB201004058D0 (en) * 2010-03-11 2010-04-28 Consiglio Nazionale Ricerche Diagnostic assay for obesity and related disorders
US20220031636A1 (en) * 2018-09-28 2022-02-03 Societe Des Produits Nestle S.A. Compounds that enhance the action of metformin
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863915A (en) * 1996-05-15 1999-01-26 Bayer Corporation Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide

Also Published As

Publication number Publication date
HUP0402241A2 (hu) 2005-02-28
JP2005515984A (ja) 2005-06-02
EP1448181B1 (en) 2006-05-31
RU2004119817A (ru) 2005-04-20
DE60211938D1 (de) 2006-07-06
CY1105165T1 (el) 2010-03-03
DE60211938T2 (de) 2007-05-24
PL369894A1 (en) 2005-05-02
ZA200405021B (en) 2005-05-30
CA2468280A1 (en) 2003-06-05
US20050020609A1 (en) 2005-01-27
BR0214487A (pt) 2004-10-19
EP1448181A1 (en) 2004-08-25
TW200300341A (en) 2003-06-01
PT1448181E (pt) 2006-10-31
CN1592615A (zh) 2005-03-09
FR2832633A1 (fr) 2003-05-30
AU2002351848A1 (en) 2003-06-10
FR2832633B1 (fr) 2004-09-24
DK1448181T3 (da) 2006-09-04
KR20040058266A (ko) 2004-07-03
ATE327746T1 (de) 2006-06-15
ES2266605T3 (es) 2007-03-01
WO2003045368A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
MY118164A (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MY141243A (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
SE0001899D0 (sv) New compounds
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
SE9900961D0 (sv) Novel compounds
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
IT1320080B1 (it) Composizione per uso farmaceutico o dietetico.
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
SE0102440D0 (sv) New compound
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
SE0000303D0 (sv) Novel compounds
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
BE2016C017I2 (es)
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal